April 2013
Physician Assistants' Prescribing Reference;Spring2013, Vol. 20 Issue 1, p147
The article offers information on contradictions, adverse reactions and warning/precautions of various drugs used for metabolic disorders including Zovirax capsules, Adipex-P teva and Bontril PDM Valent. It also presents the drug dosage which should be observed by the adults and the children so as to avoid the over usage of the drugs.


Related Articles

  • Are Carbonic Anhydrase Inhibitors Suitable for Obtaining Antiobesity Drugs? De Simone, Giuseppina; Di Fiore, Anna; Supuran, Claudiu T. // Current Pharmaceutical Design;Mar2008, Vol. 14 Issue 7, p655 

    Obesity is widespread disease both in the developed and developing world, which currently affects over 300 million individuals worldwide and is associated with premature mortality and chronic morbidity. Although diet, physical activity and behavioral modifications should theoretically help in...

  • Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Miyawaki, Kazumasa; Yamada, Yuichiro; Ban, Nobuhiro; Ihara, Yu; Tsukiyama, Katsushi; Zhou, Heying; Fujimoto, Shimpei; Oku, Akira; Tsuda, Kinsuke; Toyokuni, Shinya; Hiai, Hiroshi; Mizunoya, Wataru; Fushiki, Tohru; Holst, Jens Juul; Makino, Mitsuhiro; Tashita, Akira; Kobara, Yukari; Tsubamoto, Yoshiharu; Jinnouchi, Takayoshi // Nature Medicine;Jul2002, Vol. 8 Issue 7, p738 

    Secretion of gastric inhibitory polypeptide (GIP), a duodenal hormone, is primarily induced by absorption of ingested fat. Here we describe a novel pathway of obesity promotion via GIP. Wild-type mice fed a high-fat diet exhibited both hypersecretion of GIP and extreme visceral and subcutaneous...

  • METABOLIC DISORDERS.  // MPR - Physician Assistants' Edition;Spring2015, Vol. 22 Issue 1, p140 

    The article reviews several drugs for metabolic disorders including Contrave from Takeda, Belviq from Eisai and Adipex-P from Teva.

  • METABOLIC DISORDERS.  // MPR - Physician Assistants' Edition;Summer2015, Vol. 22 Issue 2, p142 

    The article offers information on drugs or medications indicated for metabolic disorders. These include the prescription products like Adipex-P from Teva, Contrave from Takeda and Qsymia from Vivus . It cites the recommended dosages for the drugs, their indications and contraindications, their...

  • METABOLIC DISORDERS.  // MPR - Nurse Practitioners' Edition;Summer2015, Vol. 22 Issue 2, p142 

    A list of pharmacologic products for metabolic disorders is presented, along with brief information about the drugs, including Adipex-P tablets by Teva, Belviq tablets by Eisai and Qysmia tablets by Vivus.

  • Pharmacotherapy for Obesity. Ioannides-Demos, Lisa L.; Proietto, Joseph; McNeil, John J. // Drugs;2005, Vol. 65 Issue 10, p1391 

    Pharmacotherapy for the management of obesity is primarily aimed at weight loss, weight loss maintenance and risk reduction, and has included thyroid hormone, amphetamines, phentermine, amfepramone (diethylpropion), phenylpropanolamine, mazindol, fenfluramines and, more recently, sibutramine and...

  • The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study. Mulder, H.; Franke, B.; Beek van der, A. Aart Van der; Arends, J.; Wilmink, F. W.; Egberts, A. C. G.; Scheffer, H. // Pharmacogenomics Journal;2007, Vol. 7 Issue 5, p318 

    The use of antipsychotics is associated with an increased risk of obesity. This consideration makes it important to search for determinants that can predict the risk for antipsychotic-induced obesity. In this cross-sectional study, we investigated whether polymorphisms in the HTR2C gene were...

  • Commonly Asked Questions & Answers about Obesity. Blackburn, George L. // National Women's Health Report;Oct2006, Vol. 28 Issue 4, p7 

    The article presents questions and answers related to obesity. One person asks about weight loss surgery. A reader asks about when should one consider taking weight-loss medication. Another reader asks about safety of weight-loss medication.

  • Therapeutic benefits of CB1-receptor blockade. Graham, Mark G.; Usdan, Lisa S. // Patient Care;Nov2006, Vol. 40 Issue 11, p48 

    The article explores the pharmacology of cannabinoid (CB)-receptor blockade and its potential as an effective therapeutic weapon against the health hazards posed by obesity and the metabolic syndrome. It describes the endocannabinoid system, a neuroendocrine system which controls appetite, fat...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics